Comparative Pharmacology
Head-to-head clinical analysis: DELTALIN versus DRISDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTALIN versus DRISDOL.
DELTALIN vs DRISDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Drisdol (ergocalciferol) is a vitamin D2 analog that increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and stimulates bone mineralization by binding to vitamin D receptors, which regulate gene expression.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
50,000 IU orally once weekly for 8 weeks, then 50,000 IU orally once monthly for maintenance.
None Documented
None Documented
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Terminal elimination half-life is approximately 19–48 hours after a single oral dose, with clinical context: repetitive dosing increases half-life due to accumulation in adipose tissue, leading to a functional half-life of weeks to months for vitamin D stores.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Primarily excreted via bile into feces (~90%), with renal excretion accounting for the remainder (~10%). Biliary excretion of metabolites is the major route, with enterohepatic recycling contributing to prolonged elimination.
Category C
Category C
Vitamin D Analog
Vitamin D Analog